CERTIFICATE OF NOTIFICATION
filed by
GEORGIA POWER COMPANY
Pursuant to order of the Securities and Exchange Commission dated
December 15, 1993, in the matter of File No. 70-8085.
Georgia Power Company ("GEORGIA") hereby certifies to said Commission,
pursuant to Rule 24, that, in accordance with the terms and conditions of and
for the purposes represented by the statement on Form U-1, as amended, and of
said order with respect thereto the following information is provided.
1. List of each Partnership Portfolio Company.
(a) AtheroGenics, Inc.
(b) Discovery Therapeutics, Inc.
(c) Synchrologic, Inc.
2. Fair Market Value of Partnership's Investment.
$1.2 million.
3. General description of the business activities of each such
Partnership Portfolio Company.
(a) AtheroGenics, Inc. (a Georgia-based company) is engaged in
the development of novel pharmaceuticals and diagnostic markers which
address cardiovascular disease and its intervention.
(b) Discovery Therapeutics, Inc. (a Virginia-based company) is
engaged in the development of novel therapeutic products to treat
disorders and diseases related to the signal molecules dopamine and
adenosine. Discovery Therapeutics, Inc. has agreed in principle to
relocate to Georgia.
(c) Synchrologic, Inc. (a Georgia-based company) builds
object-oriented middleware development tools to extend client/server
functionality to occasionally connected users.
4. Aggregate amount invested by GEORGIA in the Partnership during such
semi-annual period (January 1996 - June 1996).
$750,000.
<PAGE>
-2-
5. GEORGIA's aggregate investment in the Partnership at end of
June 30, 1996.
$2.5 million.
Dated: September 26, 1996 GEORGIA POWER COMPANY
By: /s/ Wayne Boston
Wayne Boston, Assistant Secretary
